Hospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (25)

2023

  1. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients

    BMC Health Services Research, Vol. 23, Núm. 1

  2. Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry

    The European respiratory journal

  3. Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin

    International Journal of COPD, Vol. 18, pp. 1691-1700

2021

  1. Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO)

    Archivos de Bronconeumologia

2020

  1. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey

    Respiratory Medicine, Vol. 170

2019

  1. Geographic distribution of chronic obstructive pulmonary disease prevalence in Africa, Asia and Australasia

    International Journal of Tuberculosis and Lung Disease, Vol. 23, Núm. 10, pp. 1100-1106

2018

  1. Alpha-1 antitrypsin deficiency: Outstanding questions and future directions

    Orphanet Journal of Rare Diseases, Vol. 13, Núm. 1

  2. Geographical Distribution of COPD Prevalence in the Americas

    COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 15, Núm. 4, pp. 317-325

  3. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique

    International Journal of COPD, Vol. 13, pp. 57-67

  4. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the spanish registry (REDAAT)

    International Journal of COPD, Vol. 13, pp. 1001-1007

2017

  1. Alpha-1 antitrypsin Pi*SZ genotype: Estimated prevalence and number of SZ subjects worldwide

    International Journal of COPD, Vol. 12, pp. 1683-1694

  2. Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: An update

    International Journal of COPD, Vol. 12, pp. 561-569

  3. Clinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry

    PLoS ONE, Vol. 12, Núm. 5

  4. Etiología de las bronquiectasias en una cohorte de 2.047 pacientes. Análisis del registro histórico español

    Archivos de Bronconeumologia, Vol. 53, Núm. 7, pp. 366-374

  5. Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency: Database Evaluation and Population Analysis

    Archivos de Bronconeumologia, Vol. 53, Núm. 1, pp. 13-18

2016

  1. Factors associated with fatality during the intensive phase of anti-tuberculosis treatment

    PLoS ONE, Vol. 11, Núm. 8

  2. Spanish Compliance With Guidelines for Prescribing Four Drugs in the Intensive Phase of Standard Tuberculosis Treatment

    Archivos de Bronconeumologia, Vol. 52, Núm. 5, pp. 262-268

  3. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 2, pp. 142-152

2015

  1. Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update

    Archivos de Bronconeumologia, Vol. 51, Núm. 4, pp. 185-192

2011

  1. Factores asociados a la evolución de la función pulmonar en pacientes con déficit de alfa-1-antitripsina del registro español

    Archivos de Bronconeumologia, Vol. 47, Núm. 10, pp. 495-503